AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-20. Numbers and descriptions here follow the published literature rather than marketing material.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
== Further reading == Davidson JA, Sloan L (January 2017). "Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview". Adv Ther. 34 (1): 41–59. doi:10.1007/s12325-016-0434-2. PMC 5216068. PMID 27854055.
On 26 August 2008, Financial Times wrote that "Most accounts agree that it was South Ossetian separatists who committed the first act of escalation when they blew up a Georgian military vehicle on August 1, wounding five Georgian peacekeeping troops." It argued: "So swift was the Russian reaction that some analysts believe that, while it did not appear to precede the Georgian assault on Tskhinvali, as Mr Saakashvili claims, it may have been planned in advance, with Mr Saakashvili simply falling into a well prepared Russian trap."
Luigi Galvani, a pioneer of medical electricity Benjamin Franklin, an early proponent of electrotherapy who made it widely known, but mostly taken up by quacks and charlatans Golding Bird, mentioned above Charles Grafton Page Duchenne de Boulogne Jacques-Arsène d'Arsonval George Miller Beard Margaret Cleaves, a promoter of ozone therapy Many of the forms of electricity used in electrotherapy were named after scientists
My fellow Americans, I'm pleased to tell you that today I signed legislation that will allow student religious groups to begin enjoying a right they've too long been denied—the freedom to meet in public high schools during non-school hours, just as other student groups are allowed to do. Following his trip to Los Angeles in 1959 and being refused entry into Disneyland, on security grounds, a dejected Soviet Premier Nikita Khrushchev joked, "... just now I was told that I could not go to Disneyland, I asked 'Why not?' What is it, do you have rocket launching pads there?" The only person more disappointed than Khrushchev was Walt Disney himself, who claimed he had been looking forward to showing off his 'submarine fleet', which was actually the Submarine Voyage ride.
Sources: en.wikipedia.org
Due to its problematic cultivation in laboratory conditions, much is still unknown about the pathogenesis of T. pallidum. In 2023, Hu YT et al. published an article about the in vitro interaction between microglia cells and T. pallidum, which could prove to be significant in case of neurosyphilis. They have confirmed underlying mechanism of how the bacteria induce microglial apoptosis and simultaneously inhibit its clearance. They have discovered that T. pallidum activates microglia and induces autophagy on one side, but on the other side it interferes with mTORC1/TFEB pathway. This pathway is an important pathway, where the inhibition of mTORC1 signalling causes the nuclear translocation of transcription factor EB (TFEB). TFEB is a master regulator of lysosome biogenesis and its translocation to the nucleus induces the transcription of lysosomal genes and the production of lysosomes. T. pallidum interferes in this pathway by activating mTORC1, which inhibits nuclear translocation of TFEB, which consequently inhibits lysosomal biogenesis and autophagic flux. That leads into accumulation of autophagosomes, which in turn leads to microglial apoptosis and prevents the clearance of T. pallidum. This study offers good foundation for further studies of T. pallidum pathogenesis and potentially new therapeutic targets.
It has been suggested that suicidal behavior and ideation may be associated with use of GLP-1 receptor-agonist medication, but studies in several countries since 2024 do not support this. In January 2026, the US Food and Drug Administration requested removal of a suicidal behavior and ideation warning from GLP-1 receptor-agonist medications.
== Function == Nidogen-1 is a member of the nidogen family of basement membrane glycoproteins. The protein interacts with several other components of basement membranes. Structurally it (along with perlecan) connects the networks formed by collagens and laminins to each other. It may also play a role in cell interactions with the extracellular matrix.
==== Type 1C ==== Type 1C VWD indicates patients with quantitative deficiency due to an enhanced VWF clearance, accounting for ~15% to 20% of cases. Such patients may require VWF concentrate to treat/prevent bleeds.
In broad terms, spent nuclear fuel has three main components. The first consists of fission products, the leftover fragments of fuel atoms after they have been split to release energy. Fission products come in dozens of elements and hundreds of isotopes, all of them lighter than uranium. The second main component of spent fuel is transuranics (atoms heavier than uranium), which are generated from uranium or heavier atoms in the fuel when they absorb neutrons but do not undergo fission. The actinide series on the periodic table runs from actinium to lawrencium and includes uranium as well as transuranic elements. The third and largest component is the remaining uranium which is around 98.25% uranium-238, 1.1% uranium-235, and 0.65% uranium-236. The U-236 comes from the non-fission capture reaction where U-235 absorbs a neutron but releases only a high energy gamma ray instead of undergoing fission. The physical behavior of the fission products is markedly different from that of the actinides. In particular, fission products do not undergo fission and therefore cannot be used as nuclear fuel. Indeed, because fission products are often neutron poisons (absorbing neutrons that could be used to sustain a chain reaction), fission products are viewed as nuclear 'ashes' left over from consuming fissile materials. Furthermore, only seven long-lived fission product isotopes have half-lives longer than a hundred years, which makes their geological storage or disposal less problematic than for transuranic materials.
Sources: en.wikipedia.org
As of 2018, all human CCEEVs available are packaged as single-dose vials containing the lyophilized vaccine. They are reconstituted by adding water prior to injection. This kind of vaccines are intended to be stored at a temperature between 2°C and 8°C (36°F to 46°F): refrigerated, not frozen.
1926–1949: Commander of the 24th Army of the National Revolutionary Army 1927–1929: Commander of the Sichuan-Xikang Defence Force 1927–1934: Chairman of Sichuan Province 1934–1939: Chairman of the Xikang Provincial Establishment Committee 1939–1949: Governor of Xikang Province 1949–1954: Vice Chairman of the Southwest Military and Political Committee 1949–1976: Member of the National Committee of the Chinese People's Political Consultative Conference 1949–1976: Member of the National People's Congress 1954–1976: Member of the Central Committee of the Revolutionary Committee of the Chinese Kuomintang 1959–1967: Minister of Forestry of the People's Republic of China
== List of specialties recognized in the European Union and European Economic Area == The European Union publishes a list of specialties recognized in the European Union, and by extension, the European Economic Area. There is substantial overlap between some of the specialties and it is likely that for example "Clinical radiology" and "Radiology" refer to a large degree to the same pattern of practice across Europe.
== Mechanism of action == Difenoxin has a high peripheral/central actions ratio, working primarily on various opioid receptors in the intestines. Although it is capable of producing significant central effects at high doses, doses within the normal therapeutic range generally do not notably impair cognition or proprioception, resulting in therapeutic activity roughly equatable to that of loperamide (Imodium). Increased dosages result in more prominent central opioid effects (and anticholingeric effects when the formulation also contains a tropane alkaloid). It therefore offers limited advantages over more potent anti-diarrheal opioid options (ex. morphine) when treating intractable cases of diarrhea which fail to respond to normal or moderately increased difenoxin doses, and may in fact be harmful in such circumstances if the formulation used also contains atropine or hyoscyamine.
McGregor divides his time between Los Angeles, California, and St John's Wood, London. McGregor enjoys travelling and is a fan of Manchester City F.C.. In 2007, on an episode of Parkinson, McGregor said he had been a teetotaller for the last seven years. He also mentioned this in an interview with the Irish Independent in 2008, stating that he would often turn up to sets drunk or hung over in the late 1990s, and that he decided to stop altogether to avoid spiralling down further. In 2008, McGregor had a cancerous mole removed from below his right eye. In September 2020, after travelling through Chile for the documentary Long Way Up, he revealed that one of his great-grandfathers, John "Juan" Charles McIndoe, was born in Chile to Scottish parents while his father worked with the American engineers in the construction of the railways at the end of the 19th century. Later, John went to Glasgow and worked as a wine importer and diplomat. McGregor became a naturalised US citizen after 2016 so he would be able to vote in the 2020 US presidential election. During his journey on Long Way Up, he travelled entirely on his US passport. He is a fan of the Fremantle Dockers in the Australian Football League. In 2025, McGregor rejoined his youth pipe band the Morrison's Academy; he invited the band to his estate in Carse of Gowrie, where he alongside the band played a special show for his parents.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.